Ensuring reliable access to affordable, safe, effective, sustainable, and high-quality 21st-century medicines requires 21st-century technologies and, crucially, harmonised, effective and innovative regulatory approaches. This UK regulatory science network aims to deliver the 21st-century regulatory science and innovation needed to unlock the benefits of the digital transformation of medicines development and manufacturing for the pharmaceutical industry, regulators, and society. The network will address sector-specific challenges, such as unclear regulatory frameworks, the complexity of AI-based models, data quality and security concerns, regulatory expertise shortages, and trust issues among patients and the public. A particular focus will be on AI and predictive models, as well as autonomous and regulatory-ready data generation through robotics and automation. This strategic initiative aims to bring the UK development, manufacturing and regulatory ecosystem together to transform these emerging digital technologies into critical components of medicines regulatory submission, assessment, and inspection by building consensus on standards to enable the digital transformation of these processes essential for delivering new medicines. The network will unite research institutions, small and medium-sized enterprises, pharma, biotech, technology vendors, and regulators to achieve its objectives. The fourfold strategy includes forging collaborations, creating evidence-based research for digital technologies, advocating and enabling regulatory science and modern practices, and providing training and translation programmes. Leveraging existing partnerships with global pharma companies, technology and software providers, academic networks, and strategic alliances with innovation centres, the network aims to drive international regulatory policy and practice in the sector and reposition regulation as an enabler of growth, able to adopt new, adaptive approaches and regulatory models. This network brings direct benefits to a range of stakeholders. By accelerating and streamlining the regulatory process, it accelerates the development of life-saving drugs, ensuring faster patient access while increasing operational efficiency and improving sustainability. Global technology providers gain advantages through seamless alignment with regulatory standards, positioning them at the forefront of innovation. In the academic sector, the network fosters collaboration between academia, industry, and regulators, contributing to a pro-innovation regulatory system, while regulators benefit from an enhanced, efficient, and digitally supported regulation system, leading to faster decision-making. The ultimate beneficiaries are the general public, as the network facilitates the accelerated supply of new, effective medicines, addressing critical healthcare needs promptly and safely and contributing to improved public health outcomes. Overall, the regulatory science and innovation network emerges as a dynamic force advancing healthcare to benefit individuals and communities.

This project is a collaboration between large UK pharmaceutical companies, academia and technology suppliers to generate a structured approach to designing age-appropriate medicines for children and technology for predicting their quality and performance. Paediatric medicine is currently a "hot-topic" within the pharmaceutical industry and there is a lot of effort going into developing such medicines for children that are acceptable in terms of taste but also provide the relevant dose and exposure required for such patients. The output will provide a smarter route to developing children’s medicines to reduce costs and time of development by determination of the most appropriate testing strategies that drive formulation design.

This project is a collaboration between large UK pharmaceutical companies, academia and technology suppliers to generate a structured approach to designing age-appropriate medicines for children and technology for predicting their quality and performance. Paediatric medicine is currently a "hot-topic" within the pharmaceutical industry and there is a lot of effort going into developing such medicines for children that are acceptable in terms of taste but also provide the relevant dose and exposure required for such patients. The output will provide a smarter route to developing children’s medicines to reduce costs and time of development by determination of the most appropriate testing strategies that drive formulation design.

This project is a collaboration between large UK pharmaceutical companies, academia and technology suppliers to generate a structured approach to designing age-appropriate medicines for children and technology for predicting their quality and performance. Paediatric medicine is currently a "hot-topic" within the pharmaceutical industry and there is a lot of effort going into developing such medicines for children that are acceptable in terms of taste but also provide the relevant dose and exposure required for such patients. The output will provide a smarter route to developing children’s medicines to reduce costs and time of development by determination of the most appropriate testing strategies that drive formulation design.

This project is a collaboration between large UK pharmaceutical companies, academia and technology suppliers to generate a structured approach to designing age-appropriate medicines for children and technology for predicting their quality and performance. Paediatric medicine is currently a "hot-topic" within the pharmaceutical industry and there is a lot of effort going into developing such medicines for children that are acceptable in terms of taste but also provide the relevant dose and exposure required for such patients. The output will provide a smarter route to developing children’s medicines to reduce costs and time of development by determination of the most appropriate testing strategies that drive formulation design.

This project is a collaboration between large UK pharmaceutical companies, academia and technology suppliers to generate a structured approach to designing age-appropriate medicines for children and technology for predicting their quality and performance. Paediatric medicine is currently a "hot-topic" within the pharmaceutical industry and there is a lot of effort going into developing such medicines for children that are acceptable in terms of taste but also provide the relevant dose and exposure required for such patients. The output will provide a smarter route to developing children’s medicines to reduce costs and time of development by determination of the most appropriate testing strategies that drive formulation design.

This project is a collaboration between large UK pharmaceutical companies, academia and technology suppliers to generate a structured approach to designing age-appropriate medicines for children and technology for predicting their quality and performance. Paediatric medicine is currently a "hot-topic" within the pharmaceutical industry and there is a lot of effort going into developing such medicines for children that are acceptable in terms of taste but also provide the relevant dose and exposure required for such patients. The output will provide a smarter route to developing children’s medicines to reduce costs and time of development by determination of the most appropriate testing strategies that drive formulation design.

This project is a collaboration between large UK pharmaceutical companies, academia and technology suppliers to generate a structured approach to designing age-appropriate medicines for children and technology for predicting their quality and performance. Paediatric medicine is currently a "hot-topic" within the pharmaceutical industry and there is a lot of effort going into developing such medicines for children that are acceptable in terms of taste but also provide the relevant dose and exposure required for such patients. The output will provide a smarter route to developing children’s medicines to reduce costs and time of development by determination of the most appropriate testing strategies that drive formulation design.

This project is a collaboration between large UK pharmaceutical companies, academia and technology suppliers to generate a structured approach to designing age-appropriate medicines for children and technology for predicting their quality and performance. Paediatric medicine is currently a "hot-topic" within the pharmaceutical industry and there is a lot of effort going into developing such medicines for children that are acceptable in terms of taste but also provide the relevant dose and exposure required for such patients. The output will provide a smarter route to developing children’s medicines to reduce costs and time of development by determination of the most appropriate testing strategies that drive formulation design.

This project is a collaboration between large UK pharmaceutical companies, academia and technology suppliers to generate a structured approach to designing age-appropriate medicines for children and technology for predicting their quality and performance. Paediatric medicine is currently a "hot-topic" within the pharmaceutical industry and there is a lot of effort going into developing such medicines for children that are acceptable in terms of taste but also provide the relevant dose and exposure required for such patients. The output will provide a smarter route to developing children’s medicines to reduce costs and time of development by determination of the most appropriate testing strategies that drive formulation design.

This project is a collaboration between large UK pharmaceutical companies, academia and technology suppliers to generate a structured approach to designing age-appropriate medicines for children and technology for predicting their quality and performance. Paediatric medicine is currently a "hot-topic" within the pharmaceutical industry and there is a lot of effort going into developing such medicines for children that are acceptable in terms of taste but also provide the relevant dose and exposure required for such patients. The output will provide a smarter route to developing children’s medicines to reduce costs and time of development by determination of the most appropriate testing strategies that drive formulation design.

This project is a collaboration between large UK pharmaceutical companies, academia and technology suppliers to generate a structured approach to designing age-appropriate medicines for children and technology for predicting their quality and performance. Paediatric medicine is currently a "hot-topic" within the pharmaceutical industry and there is a lot of effort going into developing such medicines for children that are acceptable in terms of taste but also provide the relevant dose and exposure required for such patients. The output will provide a smarter route to developing children’s medicines to reduce costs and time of development by determination of the most appropriate testing strategies that drive formulation design.

This project is a collaboration between large UK pharmaceutical companies, academia and technology suppliers to generate a structured approach to designing age-appropriate medicines for children and technology for predicting their quality and performance. Paediatric medicine is currently a "hot-topic" within the pharmaceutical industry and there is a lot of effort going into developing such medicines for children that are acceptable in terms of taste but also provide the relevant dose and exposure required for such patients. The output will provide a smarter route to developing children’s medicines to reduce costs and time of development by determination of the most appropriate testing strategies that drive formulation design.

This project is a collaboration between large UK pharmaceutical companies, academia and technology suppliers to generate a structured approach to designing age-appropriate medicines for children and technology for predicting their quality and performance. Paediatric medicine is currently a "hot-topic" within the pharmaceutical industry and there is a lot of effort going into developing such medicines for children that are acceptable in terms of taste but also provide the relevant dose and exposure required for such patients. The output will provide a smarter route to developing children’s medicines to reduce costs and time of development by determination of the most appropriate testing strategies that drive formulation design.

This project is a collaboration between large UK pharmaceutical companies, academia and technology suppliers to generate a structured approach to designing age-appropriate medicines for children and technology for predicting their quality and performance. Paediatric medicine is currently a "hot-topic" within the pharmaceutical industry and there is a lot of effort going into developing such medicines for children that are acceptable in terms of taste but also provide the relevant dose and exposure required for such patients. The output will provide a smarter route to developing children’s medicines to reduce costs and time of development by determination of the most appropriate testing strategies that drive formulation design.

This project is a collaboration between large UK pharmaceutical companies, academia and technology suppliers to generate a structured approach to designing age-appropriate medicines for children and technology for predicting their quality and performance. Paediatric medicine is currently a "hot-topic" within the pharmaceutical industry and there is a lot of effort going into developing such medicines for children that are acceptable in terms of taste but also provide the relevant dose and exposure required for such patients. The output will provide a smarter route to developing children’s medicines to reduce costs and time of development by determination of the most appropriate testing strategies that drive formulation design.

This project is a collaboration between large UK pharmaceutical companies, academia and technology suppliers to generate a structured approach to designing age-appropriate medicines for children and technology for predicting their quality and performance. Paediatric medicine is currently a "hot-topic" within the pharmaceutical industry and there is a lot of effort going into developing such medicines for children that are acceptable in terms of taste but also provide the relevant dose and exposure required for such patients. The output will provide a smarter route to developing children’s medicines to reduce costs and time of development by determination of the most appropriate testing strategies that drive formulation design.

This project is a collaboration between large UK pharmaceutical companies, academia and technology suppliers to generate a structured approach to designing age-appropriate medicines for children and technology for predicting their quality and performance. Paediatric medicine is currently a "hot-topic" within the pharmaceutical industry and there is a lot of effort going into developing such medicines for children that are acceptable in terms of taste but also provide the relevant dose and exposure required for such patients. The output will provide a smarter route to developing children’s medicines to reduce costs and time of development by determination of the most appropriate testing strategies that drive formulation design.

This project is a collaboration between large UK pharmaceutical companies, academia and technology suppliers to generate a structured approach to designing age-appropriate medicines for children and technology for predicting their quality and performance. Paediatric medicine is currently a "hot-topic" within the pharmaceutical industry and there is a lot of effort going into developing such medicines for children that are acceptable in terms of taste but also provide the relevant dose and exposure required for such patients. The output will provide a smarter route to developing children’s medicines to reduce costs and time of development by determination of the most appropriate testing strategies that drive formulation design.

This project is a collaboration between large UK pharmaceutical companies, academia and technology suppliers to generate a structured approach to designing age-appropriate medicines for children and technology for predicting their quality and performance. Paediatric medicine is currently a "hot-topic" within the pharmaceutical industry and there is a lot of effort going into developing such medicines for children that are acceptable in terms of taste but also provide the relevant dose and exposure required for such patients. The output will provide a smarter route to developing children’s medicines to reduce costs and time of development by determination of the most appropriate testing strategies that drive formulation design.